Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use
Author(s): Teimouri Arezou, Yeung Pollen, Agu Remigius U
Issue: Nov/Dec 2020 - Volume 24, Number 6
View All Articles in Issue
Page(s): 482-490
Download in electronic PDF format for $75
Abstract: Interest in the topical use of compounded diltiazem has increased. Published information on the stability of such products is scarce. The objective of this study was to investigate the stability of diltiazem hydrochloride compounded in cream (Glaxal Base), ointment (white petrolatum), and hydroxyethyl cellulose-based gel over 90 days at room (23°C), refrigerator (4°C), and elevated (40°C) temperatures, stored in white plastic and glass amber containers. Organoleptic properties, pH changes, and United States Pharmacopeia recommendations were used for assigning beyond-use-dates. The results showed that the currently recommended United States Pharmacopeia beyond-use date of 30 days is acceptable for diltiazem (2%) in Glaxal Base at 4°C and 23°C in either white plastic or glass amber jars. The cream, however, is not recommended for use if exposed to elevated temperatures (40°C) in white plastic jars but may be used within 7 days if stored in glass amber jars. A beyond-use date of 90 days for diltiazem (2%) hydroxyethyl cellulose-based gel, when maintained at 4°C or 23°C, in either white plastic or glass amber jars, is recommended. Gels exposed to elevated temperatures (40°C) should be used within14 and 30 days in glass amber and white plastic jars, respectively. Lastly, a BUD of 90 days for diltiazem (2%) ointment (white petrolatum) at 23°C stored in either jar type is acceptable. Ointment formulations exposed to elevated temperatures (40°C) may be used within 7 days in white plastic jars. Diltiazem (2%) in white petrolatum should not be stored at 4°C.
Related Keywords:
diltiazem hydrochloride, topical preparations, calcium channel blocker, chronic anal fissures, diabetic ulcers, stability, storage conditions, commercial bases, temperature
Related Categories:
DERMATOLOGY, DIABETES, EXCIPIENTS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, DOSAGE FORMS/DRUG CARRIERS, STORAGE
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use
Teimouri Arezou, Yeung Pollen, Agu Remigius U
|
Nov/Dec 2020
Pg. 482-490
|
Current Topical Treatments in Wound Healing - Part 1
Helmke Christopher D
|
Jul/Aug 2004
Pg. 269-274
|
Five Compounds for Treating Diabetes-Related Conditions
Meece Jerry
|
May/Jun 2003
Pg. 170-174
|
Drug-release Assessment of Compounded Topical Nifedipine and Diltiazem in Commonly Used Bases for Wound Healing
Teimouri Arezou, Yeung Pollen, Agu Remigius U
|
Nov/Dec 2020
Pg. 501-508
|
Stability of Compounded Topical Nifedipine in Cream, Gel, and Ointment Bases
Teimouri Arezou, Yeung Pollen, Agu Remigius U
|
Jul/Aug 2021
Pg. 344-351
|
Case Report: Wound Care of a Diabetic Foot Ulcer
Wynn Tom
|
Jul/Aug 2004
Pg. 265-267
|
Compounding Pearls -- Wound Care: Diabetic Foot Ulcers, Part 1
Riepl Mike
|
May/Jun 2020
Pg. 182-186
|
Case Report of Anal Fissures and Hemorrhoids Treated with Compounded Cromolyn Sodium and Naltrexone Hydrochloride in MEDISCA's SPG SUPPOSI-BASE
Earlywine Kerry, Haiub Halema, Cull Erica, Lupatini Rodrigo, Sidhu Raman
|
Jan/Feb 2023
Pg. 6-10
|
Diltiazem Hydrochloride 12 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
|
Nov/Dec 2018
Pg. 493
|
Basics of Compounding for Cold Sores or Fever Blisters
Allen Loyd V Jr
|
May/Jun 2004
Pg. 206-209
|
Diltiazem Hydrochloride 5-mg/mL Injection
Allen Loyd V Jr
|
May/Jun 2012
Pg. 241
|
Case Report: Diabetic Foot Ulcer Infection Treated with Topical Compounded Medications
Agbi Kelechi E, Carvalho Maria, Phan Ha, Tuma Cristiane
|
Jan/Feb 2017
Pg. 22-27
|
Novel Approaches to Topical Psoriasis Therapy
Koyama Gregory, Liu Jenny, Scaffidi Alyse, Khazraee Maryam, Epstein Benjamin
|
Sep/Oct 2015
Pg. 357-365
|
A Compendium of Compounding Agents and Formulations, Part 6: Additional Preparations for Refractory Dermal-wound Healing
Riepl Mike
|
Nov/Dec 2022
Pg. 480-488
|
Stability of Atenolol, Clonazepam, Dexamethasone, Diclofenac Sodium, Diltiazem, Enalapril Maleate, Ketoprofen, Lamotrigine, Penicillamine-D, and Thiamine in SyrSpend SF PH4 Oral Suspensions
Polonini HC, Loures S, Lima LC, Ferreira AO, Brandão MA
|
Mar/Apr 2016
Pg. 167-174
|
Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride
Alexander Kenneth S, Thyangarajapuram N
|
Sep/Oct 2003
Pg. 389-393
|
Development and Application of a High-Performance Liquid Chromatography Stability-Indicating Assay for Beyond-Use Date Determination of Compounded Topical Gels Containing Multiple Active Drugs
Gorman Gregory, Sokom Simara, Coward Lori, Arnold John J
|
Mar/Apr 2017
Pg. 164-170
|
Skin Permeation and Antinociception of Compounded Topical Cyclobenzaprine Hydrochloride Formulations
Bryson Evan, Hartman Rachel, Arnold John, Gorman Greg, Sweitzer Sarah.Asbill Scott
|
Mar/Apr 2015
Pg. 161-166
|
In Vitro Permeability, Irritability, and Release Evaluation of Commonly Used Topical Diclofenac Gel Preparations (1%, 5%, and 10%)
Kohan Hamed Gilzad, Baker David M, Sani Shabnam, Bielecki-Wilken Kathleen A, Ramirez Alfonso
|
Mar/Apr 2021
Pg. 146-155
|
A Compendium of Compounding Agents and Formulations, Part 4: Nifedipine and Pentoxifylline
Riepl Mike
|
Jul/Aug 2022
Pg. 270-274
|
Return to Top |